Health Care Week in Review March 20, 2020

Alston & Bird Health Care Week in Review, March 20, 2020

Below is Alston & Bird’s Health Care Week in Review, which provides a synopsis of the latest news in healthcare regulations, notices, and guidance; federal legislation and congressional committee action; reports, studies, and analyses; and other health policy news.

Week in Review Highlight of the Week:

This edition of the Week in Review contains major updates on various regulatory actions along with reports and studies recently released.


For a full update on coronavirus actions, visit the Coronavirus Flash Update, here.


I. Regulations, Notices, & Guidance

Event Notice

  • April 15, 2020: the National Institutes of Health (NIH) announced a Committee meeting of the National Institute of Allergy and Infectious Diseases Special Emphasis Panel NIAID Resource-Related Research Projects.
  • April 16, 2020: the FDA announced a public meeting entitled, Scientific and Ethical Considerations for the Inclusions of Pregnant Women in Clinical Trials. The meeting is intended to gather industry, patient, clinician, researcher, institutional review board, ethicist, professional society and other stakeholder input on the scientific and ethical issues that surround the inclusion of pregnant women in clinical trials for drug development.

II. Congressional Hearings

U.S. Senate

  • No health care-related hearings this week.

House of Representatives

  • No health care-related hearings this week.

III. Reports, Studies, & Analyses

  • On March 20, 2020, the Congressional Budget Office (CBO) issued a report entitled, Baseline Budget Projections as of March 6, 2020. The document provides the CBO’s spring 2020 baseline budget projections and explains how they differ from the projections published earlier this year.

IV. Other Health Policy News

Click here to view the members of our Health Care Legislative & Public Policy team.

Media Contact
Alex Wolfe
Communications Director

This website uses cookies to improve functionality and performance. For more information, see our Privacy Statement. Additional details for California consumers can be found here.